全文获取类型
收费全文 | 19105篇 |
免费 | 1219篇 |
国内免费 | 96篇 |
专业分类
耳鼻咽喉 | 176篇 |
儿科学 | 523篇 |
妇产科学 | 385篇 |
基础医学 | 2177篇 |
口腔科学 | 334篇 |
临床医学 | 1582篇 |
内科学 | 4023篇 |
皮肤病学 | 241篇 |
神经病学 | 1031篇 |
特种医学 | 642篇 |
外科学 | 3310篇 |
综合类 | 742篇 |
一般理论 | 17篇 |
预防医学 | 1449篇 |
眼科学 | 508篇 |
药学 | 1849篇 |
中国医学 | 219篇 |
肿瘤学 | 1212篇 |
出版年
2023年 | 171篇 |
2022年 | 518篇 |
2021年 | 657篇 |
2020年 | 423篇 |
2019年 | 532篇 |
2018年 | 640篇 |
2017年 | 450篇 |
2016年 | 368篇 |
2015年 | 516篇 |
2014年 | 712篇 |
2013年 | 875篇 |
2012年 | 1307篇 |
2011年 | 1274篇 |
2010年 | 759篇 |
2009年 | 592篇 |
2008年 | 1020篇 |
2007年 | 1001篇 |
2006年 | 922篇 |
2005年 | 848篇 |
2004年 | 774篇 |
2003年 | 697篇 |
2002年 | 587篇 |
2001年 | 556篇 |
2000年 | 492篇 |
1999年 | 404篇 |
1998年 | 189篇 |
1997年 | 153篇 |
1996年 | 138篇 |
1995年 | 134篇 |
1994年 | 87篇 |
1993年 | 97篇 |
1992年 | 207篇 |
1991年 | 193篇 |
1990年 | 168篇 |
1989年 | 182篇 |
1988年 | 146篇 |
1987年 | 177篇 |
1986年 | 131篇 |
1985年 | 146篇 |
1984年 | 114篇 |
1983年 | 93篇 |
1982年 | 73篇 |
1981年 | 65篇 |
1979年 | 98篇 |
1978年 | 72篇 |
1977年 | 70篇 |
1976年 | 56篇 |
1975年 | 65篇 |
1974年 | 51篇 |
1973年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Children with severe neurological impairment have a high incidence of respiratory problems which are multifactorial and may be related to or dependent on the underlying disability. In addition, common respiratory conditions such as asthma will be represented in this group as in the general paediatric population. In order to maximise quality of life and reduce morbidity and mortality, each child should be carefully assessed and treated, making adjustments where necessary in the treatment regime to take account of the disability. 相似文献
42.
Glatiramer acetate is an immunomodulating drug used in the treatment of multiple sclerosis. It consists of a copolymer of amino acid residues in the same stoichiometric proportions as in myelin basic protein. Its mechanism of action is not entirely known and is probably multifaceted, with deletion of some immune cell populations and stimulation of others in these patients. Some mechanisms involve neuroprotectant effects. There is ample evidence of its efficacy in relapsing-remitting disease, using both clinical and imaging measures of disease activity, and in this paper we review the clinical and basic studies of this drug. Finally we discuss how some of its neuroprotectant effects may be useful in neurodegeneration such as is seen in more advanced cases of multiple sclerosis and other diseases such as amyotrophic lateral sclerosis and Parkinson’s disease. 相似文献
43.
BACKGROUND: We assessed suicide and suicide attempt risk as well as symptom reduction among 3,282 depressed patients participating in duloxetine and escitalopram clinical trials assigned to either an antidepressant or placebo. METHODS: We reviewed the FDA Summary Basis of Approval reports for data regarding safety and efficacy for duloxetine and escitalopram. Furthermore, we compared suicide risk among antidepressant clinical trials in this study with our two previous analyses on seven antidepressant clinical trials. RESULTS: Suicide and suicide attempt risk varied considerably among the three analyses, showing up to ten fold differences. Interestingly, the variability exists across the three reports, rather than between treatments (antidepressants versus placebo). CONCLUSIONS: These findings suggest caution in generalizing suicide risk even from a relatively large number of participants and thus, firm conclusions can only be drawn if the number of participants is overwhelmingly large (approximately two million patients). We also noted similar magnitude of response to placebo and antidepressants among the three studies. 相似文献
44.
Eight cases of spinal brucellosis are included in this study. Diagnosis was established by positive serology. Back pain was the most common complaint. Functional disturbance in walking was observed in three cases; in two others this was because of impairment of cord function. Clinical hepatosplenomegaly was found in one case. Subclinical organomegaly was diagnosed in two other patients. Psoas abscess was identified by computed tomographic scan in two separate cases. Response to drug therapy and surgical decompression, when indicated, resulted in complete recovery in all patients. 相似文献
45.
46.
47.
48.
49.
Comorbidities in head and neck cancer: agreement between self-report and chart review. 总被引:1,自引:1,他引:0
Shraddha S Mukerji Sonia A Duffy Karen E Fowler Mumtaz Khan David L Ronis Jeffrey E Terrell 《Otolaryngology--head and neck surgery》2007,136(4):536-542
OBJECTIVES: To determine the accuracy of self-reported comorbidities compared with medical record review and the clinical and sociodemographic characteristics associated with accuracy of self-reported comorbidities. STUDY DESIGN: We conducted a prospective study of 458 newly diagnosed head and neck cancer patients using self-administered questionnaire and medical chart review data. Overall and itemwise consistency between self-report and chart review was evaluated. Social, clinical, and demographic characteristics of consistent versus inconsistent responders were analyzed. RESULTS: Seventy-four percent of patients had at least one comorbidity. There was good overall consistency between self-report and chart review (kappa = 0.50). Compared with consistent responders, inconsistent responders were found to be older (P < 0.05), have lower sleep (P < 0.05) and physical activity scores (P < 0.05), be more depressed (P < 0.05), and have more severe comorbidities (P < 0.05). CONCLUSIONS AND SIGNIFICANCE: Self-report may be considered as an alternative to chart review for comorbidity assessment in head and neck cancer patients. Younger patients, those with good general health, fewer depressive symptoms, and mild comorbidities, are more likely to give responses consistent with chart review. 相似文献
50.
Seema Khan Smita Singhal Tarun Mathur Dilip J Upadhyay Ashok Rattan 《Nippon Ishinkin Gakkai Zasshi》2007,48(3):109-113
Disulfiram, an alcohol antagonistic drug has been on the market since 1949 with 80% bioavailability and an established safety profile. Recently it has been reported as a P-glycoprotein efflux pump modulator. Herein we report its antifungal potential. The MIC50 and MIC90 of disulfiram for yeast isolates is 4 and 8 microg/ml, respectively, and the MIC range is 1-16 micro g/ml for both fluconazole sensitive and resistant strains. Interestingly, disulfiram also showed fungicidal activity on Aspergillus spp. with MIC50 and MIC90 of 2 and 8 microg/ml, respectively. 相似文献